Skip to main content
Top
Published in:

Open Access 12-05-2024 | Breast Cancer | Correction

Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

Authors: Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji

Published in: Breast Cancer | Issue 4/2024

Login to get access
Metadata
Title
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment
Authors
Yutaka Yamamoto
Chikako Yamauchi
Tatsuya Toyama
Shigenori Nagai
Takehiko Sakai
Goro Kutomi
Michio Yoshimura
Masaaki Kawai
Shoichiro Ohtani
Kazunori Kubota
Kazutaka Nakashima
Naoko Honma
Masayuki Yoshida
Eriko Tokunaga
Naruto Taira
Hiroji Iwata
Shigehira Saji
Publication date
12-05-2024
Publisher
Springer Nature Singapore
Published in
Breast Cancer / Issue 4/2024
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-024-01589-z

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video